China Securities Intelligent Finance News Yifan Pharmaceutical(002019) announced on February 3 that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received vitamin approval and certification from the National Medical Products Administration on January 30, 2026.K1 Injection Drug Registration Certificate

According to the announcement, the approved vitamin K1 injection solution has a specification of 1ml:10mg and is suitable for adults and children over 1 year old. It is used to treat vitamin K deficiency bleeding and prevent vitamin K deficiency that cannot be addressed through nutritional supplementation. According to data from Menet.com, the domestic sales of vitamin K1 injection solution in 2023 reached 593 million yuan. To date, several companies in China have received approval for this drug. Our company is one of two companies whose products are micellar formulations and are considered to have passed the generic drug consistency evaluation. Several other companies have generic versions under review for approval.

The announcement stated that obtaining this certificate expands the indications and target population for the company's product, thereby enhancing its overall competitiveness in the pharmaceutical field.

https://finance.eastmoney.com/a/202602033639540724.html